Novo Nordisk A/S (NVO)
NYSE · Healthcare · Drug Manufacturers - General
Novo Nordisk A/S is a Healthcare company with a market capitalization of $212.80B, a trailing P/E ratio of 11.6, and a dividend yield of 3.75%.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025 · in DKK
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 6, 2026 | $6.63 | $6.96 | -4.7% |
| Q4 2025 | February 3, 2026 | $6.04 | $5.90 | +2.4% |
| Q3 2025 | November 5, 2025 | $4.50 | $4.24 | +6.1% |
| Q2 2025 | August 6, 2025 | $5.96 | $6.00 | -0.7% |
| Q1 2025 | May 7, 2025 | $6.53 | $6.07 | +7.6% |
| Q4 2024 | February 5, 2025 | $6.34 | $6.12 | +3.6% |
Other Drug Manufacturers - General Stocks
Frequently Asked Questions
What is Novo Nordisk A/S's market cap?
As of June 29, 2026, Novo Nordisk A/S (NVO) has a market capitalization of $212.80B.
What is Novo Nordisk A/S's P/E ratio?
Novo Nordisk A/S trades at a trailing price-to-earnings (P/E) ratio of 11.6. Its forward P/E is 14.3.
Does Novo Nordisk A/S pay a dividend?
Yes — Novo Nordisk A/S pays a dividend yielding 3.75%, an annual payout of $11.70 per share.
What sector is NVO in?
Novo Nordisk A/S is in the Healthcare sector, specifically the Drug Manufacturers - General industry.
What was Novo Nordisk A/S's revenue?
In its latest reported fiscal year (ending December 31, 2025), Novo Nordisk A/S reported revenue of 309.06B DKK and net income of 102.43B DKK.
Ask your own questions about NVO
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.